Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer

(Updated) Docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide each when administered with ADT, represent five separate standards of care (SOCs) for noncastrate metastatic prostate cancer. With the exception of the triplet therapies of docetaxel plus abiraterone plus ADT and docetaxel plus darolutamide plus ADT, the use of any of these agents in any other particular combination or in any particular series cannot yet be recommended. ( EB , , , S )